{"id":"NCT02853305","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)","officialTitle":"A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-15","primaryCompletion":"2020-04-29","completion":"2022-09-15","firstPosted":"2016-08-02","resultsPosted":"2021-05-20","lastUpdate":"2023-09-08"},"enrollment":1010,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Urothelial Carcinoma Associated 1 RNA, Human"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Gemcitabine","otherNames":[]}],"arms":[{"label":"Pembrolizumab + ST Chemotherapy (Pembro Combo)","type":"EXPERIMENTAL"},{"label":"Pembrolizumab (Pembro)","type":"EXPERIMENTAL"},{"label":"ST Chemotherapy (Chemo)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine the efficacy and safety of pembrolizumab (pembro, MK-3475) with or without chemotherapy versus chemotherapy alone in participants with advanced or metastatic urothelial carcinoma (bladder cancer).\n\nThe primary hypotheses are that pembrolizumab plus chemotherapy is superior to chemotherapy alone with respect to Progression-free Survival (PFS) and Overall Survival (OS) in all participants, and that pembrolizumab alone is superior to chemotherapy alone with respect to OS in all participants and in participants with programmed cell death ligand 1 (PD-L1) positive tumors (Combined Positive Score \\[CPS\\] ≥10%).","primaryOutcome":{"measure":"Pembro Combo vs Chemo: Progression-free Survival (PFS) Using Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 42 months","effectByArm":[{"arm":"Pembrolizumab + ST Chemotherapy (Pembro Combo)","deltaMin":8.3,"sd":null},{"arm":"ST Chemotherapy (Chemo)","deltaMin":7.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0033"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":16},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["40037029","38823511","37699333","34051178"],"seeAlso":["https://www.merckclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":189,"n":349},"commonTop":["Anaemia","Nausea","Fatigue","Decreased appetite","Constipation"]}}